Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Tivozanib Hydrochloride

DRUG

paclitaxel

DRUG

Placebo

Trial Locations (54)

3204

Bentleigh

10001

New York

10453

The Bronx

21201

Baltimore

27514

Chapel Hill

30301

Atlanta

32034

Jacksonville

33018

Miami

35005

Birmingham

37501

Memphis

46077

Indianapolis

46774

Fort Wayne

57101

Sioux Falls

58102

Fargo

60007

Chicago

60456

Oak Lawn

63101

St Louis

63454

Hanau

75001

Dallas

77550

Galveston

01841

Boston

02129

Charleston

Unknown

Port Macquarie

Woodville South

Newcastle

South Brisbane

St Leonards

Calgary

Edmonton

Vancouver

Toronto

Saint John

Berlin

Cologne

Leipzig

Münster

Tübingen

Avellino

Milan

Roma

Torino

Viterbo

Seoul

Barcelona

Madrid

Málaga

Seville

Kaohsiung City

Taipei

Nassau

Dnipropetrovsk

Donetsk

Uzhhorod

Vinnytsia

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

lead

AVEO Pharmaceuticals, Inc.

INDUSTRY